Malignant neoplasm of lower lobe, unspecified bronchus or lung
ICD-10 C34.30 is a billable code used to indicate a diagnosis of malignant neoplasm of lower lobe, unspecified bronchus or lung.
C34.30 refers to a malignant neoplasm located in the lower lobe of the lung or bronchus, where the specific site is not further specified. Lung cancer is a leading cause of cancer-related mortality worldwide, often linked to risk factors such as smoking, environmental pollutants, and genetic predispositions. The lower lobe of the lung is a common site for primary lung tumors, which can present as adenocarcinoma, squamous cell carcinoma, or small cell lung cancer. Diagnosis typically involves imaging studies such as CT scans, followed by biopsy for histological confirmation. Staging of lung cancer is crucial for determining prognosis and treatment options, utilizing the TNM classification system (Tumor, Node, Metastasis). Molecular markers, including EGFR mutations and ALK rearrangements, play a significant role in targeted therapies. Treatment algorithms may include surgery, chemotherapy, radiation therapy, and immunotherapy, tailored to the stage and molecular profile of the tumor.
Detailed pathology reports, imaging studies, and treatment plans must be documented.
Initial diagnosis of lung cancer, staging workup, and treatment planning.
Ensure accurate documentation of molecular testing results and treatment response.
Comprehensive pulmonary function tests and imaging studies are essential.
Management of lung cancer symptoms and complications, such as pleural effusion.
Document any co-morbid respiratory conditions that may affect treatment.
Used for surgical resection of the lower lobe tumor.
Operative report detailing the procedure and findings.
Oncology and thoracic surgery must coordinate documentation.
Staging is crucial as it determines the extent of the disease, guides treatment options, and helps predict prognosis. Accurate staging requires detailed imaging and pathology reports.
